Eyenovia, which is developing micro-formulations of common eye therapies, announced terms for its IPO on Tuesday.
The New York, NY-based company plans to raise $30 million by offering 2.7 million shares at a price range of $10 to $12. Insiders intend to purchase $5 million worth of shares in the offering. At the midpoint of the proposed range, Eyenovia would command a fully diluted market value of $125 million.
Eyenovia was founded in 2014 and plans to list on the Nasdaq under the symbol EYEN. Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. It is expected to price during the week of January 22, 2018.
